69.70
+1.75%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Icares Medicus
Its shares trade on Taipei Exchange under the ticker 6612.TWO. It has been listed since 27 December 2016. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.13bn and net income of TWD 51.2m. At that date it held total assets of TWD 3.18bn and shareholders' equity of TWD 1.83bn.
ICARES Medicus, Inc. engages in the business of designing, development, manufacturing, and sale of intraocular lenses and nanomedical devices. The company is headquartered in Zhubei, Hsinchu. The company went IPO on 2016-12-27. The firm is also involved in the sale of surface treatment formulations and provision of customer surface treatment processing services, as well as the research and development, manufacture and sale of artificial lens and its implantation system. The firm's product revenue is mainly divided into three categories. The royalty income comes from the authorization of implantation/invasive high-end medical material surface treatment technology. The technical service income mainly includes implantation/invasive high-end medical surface treatment services, provision of medical coatings and foundry of artificial lens implantation systems. The sales of medical materials mainly include the sales of medical materials surface inspection equipment and other products. The firm distributes its products in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 27 Dec 2016
- Website
- icaresmedicus.com ↗
Leadership
Pay as last reported
- Mr. Ih-Houng LohChairman of the Board, since 2025
- Mr. William LeeVice Chairman of the Board, since 2024
- Ms. Tan-Li ChenGroup Chief Financial Officer, Head of Finance & Accounting, Corporate Governance Officer, since 2024
- Bingchun ChenGeneral Manager
- Mr. Chun-Ming LinDeputy General Manager-Operation
- Mr. Robert CummingsGeneral Manager-Subsidiary
- Mr. Kai-Yuan TanDirector
- Mr. Wen-Chu TsengDirector
- Mr. Ying-Zong YanDirector
- Mr. Jhih-Ying GuoIndependent Director
- Zhiqiu GuoIndependent Director
- Yuru XieIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Zhubei, Hsinchu, Taiwan
- Engages in designing, developing, manufacturing, and selling intraocular lenses and nanomedical devices
- Generates royalty income from authorization of implantation/invasive high-end medical material surface treatment technology
Weaknesses
- Relies on royalty income from surface treatment technology authorization
- Product revenue divided into three categories without specified details
- No mention of financial performance or market share data
Opportunities
- Expanding distribution in domestic and overseas markets
- Potential growth in artificial lens and implantation system sales
- Opportunities in research and development of medical coatings
Threats
- Dependence on unverified royalty income streams
- Lack of transparency in product revenue categories
- No information on competitive landscape or market challenges
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.